Thomas Stinchcombe Discusses Immunotherapy Breakthroughs for Lung Cancer
Immunotherapies have strong potential as a treatment option for patients with NSCLC, as clinical trials have shown dramatic and durable results.
Thomas Stinchcombe, co-director of the multidisciplinary thoracic oncology program at the University of North Carolina at Chapel Hill, shares the potential of immunotherapies in non-small cell lung cancer (NSCLC).
Stinchcombe says immunotherapies have strong potential as a treatment option for patients with NSCLC, as clinical trials have shown dramatic and durable results.
Immunotherapies will hopefully become a new option for patients with NSCLC in the near future, Stinchcombe predicts, adding there is a higher tolerance in terms of side effects.
Because EGFR and ALK mutations are often found in a smaller group of patients, immunotherapies can possibly apply to a broader spectrum of patients.
